Health
Efficacy, safety, and lot-to-lot immunogenicity of an inactivated SARS-CoV-2 vaccine (BBV152): interim results of a randomised, double-blind, controlled, phase 3 trial – The Lancet
BBV152 was highly efficacious against laboratory-confirmed symptomatic COVID-19 diseasein adults. Vaccination was well tolerated…
We use cookies to help provide and enhance our service and tailor content and ads. To update your cookie settings, please visit the Cookie Preference Center for this site.Copyright © 2021 Elsevier Inc. except certain content provided by third parties. The…
Continue Reading
-
General19 hours agoStar Wars’ fascist dystopia has never felt closer than in new season of Andor
-
Business17 hours ago10 high-conviction ASX dividend shares to buy for passive income today
-
General23 hours agoCoalition to chart path forward as family feud cooled
-
Noosa News22 hours agoInterest rates: Why we will keep paying the same repayments